Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience

Elizabeth Yasmine Wardoyo, Anggraini Permata Sari, Aryan Y Djojo, Johanes Sarwono, Md Ikhsan Mokoagow, Nikko Darnindro, Jerry Nasarudin, Marina Epriliawati, Annela Manurung, Martha Iskandar, Krishna Adi Wibisana, Anak Agung Arie Widyastuti, Radhiyatam Mardiyah


Mortality rate among maintenance hemodialysis (HD) patients with COVID-19 is alarmingly high. In Fatmawati General Hospital, most of HD patients with COVID-19 presented with acute respiratory distress syndrome (ARDS). Hemoperfusion (HP) is a blood purification therapy used to remove cytokines and inflammatory mediators to prevent ARDS worsening and organ failure. We report 6 cases of COVID-19 in maintenance HD patients. HP and HD were performed in two consecutive days when patient developed early ARDS as indicated by inflammatory markers elevation. HP and HD were conducted by using resin-containing cartridge and high-flux dialyzer, respectively, for 4 hours. Improvements in CRP levels, PaO2/FiO2 ratios, and chest X-rays were observed after 2 sessions of HP in most of our patients. Based on our clinical experience, the timing of HP delivery is critical and should be undertaken in the early phase of ARDS, but larger studies are still needed.


hemoperfusion; hemodialysis; COVID-19; cytokines; resin


Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication in critically ill COVID-19. Clin Immunol. 2020;214:108408.

Ronco C, Reis T, de Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: Si vis pacem para bellum. Blood Purif. 2020;49:255–8.

Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during covid-19 pandemic: expert review and recommendation. Blood Purif. 2020;1–11. doi:10.1159/000508125.

Ragab D, Eldin S, Taeimah M, et al. The COVID-19 cytokine storm; What we know so far. Front Immunol. 2020;11:1–4.

Safari S, Salimi A, Zali A, et al. Extracorporeal hemoperfusion as a potential therapeutic option for severe COVID-19 patients: a narrative review. Arch Acad Emerg Med. 2020;8:e67.

Winchester J. Dialysis techniques: hemoperfusion. Replacement of renal function by dialysis. In: Horl W H, Koch K, Lindsay R, Ronco C, Winchester J. Springer; 2004. p. 725–38.

Huang Z, Wang SR, Yang Z, et al. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2013;17:454–61.

Huang Z, WangSR, Su W, et al. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14:596–602.

Sun S, He L, Bai M, et al. High-volume hemofltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: A controlled pilot study. Ann Saudi Med. 2015;35:352–8.

Ranieri VM. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307:2526–33.

Asgharpour M. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19). BMC Nephrol. 2020;21.

Vardanjani EA. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19. Blood Purif. 2020; 3848176941:8–11.

Du Y, Qi Z, Ma J, et al. Case report: A patient with COVID-19 who benefited from hemoadsorption. Front Med. 2020;7:1–5.

Mezger M. Sequential use of hemadsorption using Cytosorb® and Biosky® filter-technology in a COVID-19 patient suffering from severe ARDS. Arch Clin Med Case Reports. 2020;04:969–77.

Moradi H, Abbasi S. Hemoperfusion as a supportive treatment in a COVID-19 patient with late pulmonary thromboembolism: A case report. Int Med Case Rep J. 2020;13:341–5.

Shadvar K, Tagizadiyeh A, Gamari AA, et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif. 2020;5157663314.

Ankawi G, Fan W, Montin DP. et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purif. 2019;47: 94–100.

Hajian S, Rastgoo N. The effect of hemoperfusion on the recovery of COVID-19 in hospitalized patients; case series and review study. 2021;7:4–7.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.